Pharmacophore modeling, 3D-QSAR and molecular docking studies of benzimidazole derivatives as potential FXR agonists

References

• Chen J, Yongfong L, Liu Y, et al. Extract of Cyclosorus acuminatus attenuates diabetic nephropathy in mice via modifying peroxisome proliferators activated receptor signaling pathway. Food Chem 2011;128:659–66
   Web of Science ®Google Scholar
• Li JC, Shen XF, Meng XL. A traditional Chinese medicine JiuHuangLian (Rhizoma coptidis steamed with rice wine) reduces oxidative stress injury in type 2 diabetic rats. Food Chem Toxicol 2013;59:222–9
   PubMed Web of Science ®Google Scholar
• Yu D, Mattern DL, Forman BM. An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR). Steroids 2012;77:1335–8
   PubMed Web of Science ®Google Scholar
• Epifano F, Genovese S, James Squires E, et al. The active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist. Bioorg Med Chem Lett 2012;22:3130–5
   Google Scholar
• Lin HR. Triterpenes from Alisma orientalis act as farnesoid X receptor agonists. Bioorg Med Chem Lett 2012;22:4787–92
   PubMed Web of Science ®Google Scholar
• Bjursell M, Wedin M, Admyre T, et al. Ageing FXR deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 2013;8:e64721. doi:10.1371/journal.poe.0064721
   PubMed Web of Science ®Google Scholar
• Jin L, Feng X, Rong H, et al. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun 2013;4:1937
   PubMed Web of Science ®Google Scholar
• Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2013;368:17–29
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006;103:1006–11
   PubMed Web of Science ®Google Scholar
• Duran-Sandoval D, Cariou B, Percevault F, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005;280:29971–9
   PubMed Web of Science ®Google Scholar
• Renga B, Mencarelli A, Vavassori P, et al. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta 2010;1802:363–73
   PubMed Web of Science ®Google Scholar
• Popescu IR, Helleboid-Chapman A, Lucas A, et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett 2010;584:2845–51
   PubMed Web of Science ®Google Scholar
• Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 2007;56:2485–93
   PubMed Web of Science ®Google Scholar
• Levi M. Nuclear receptors in renal disease. Biochim Biophys Acta 2011;1812:1061–7
   Google Scholar
• Wang XX, Jiang T, Shen Y, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol 2009;297:F1587–96
   PubMed Web of Science ®Google Scholar
• Shah K, Chhabra S, Shrivastava SK, Mishra P. Benzimidazole: a promising pharmacophore. Med Chem Res 2013;22:5077–104
   Web of Science ®Google Scholar
• Bansal Y, Silakari O. The therapeutic journey of benzimidazoles: a review. Bioorg Med Chem 2012;20:6208–36
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574–82
   PubMed Web of Science ®Google Scholar
• Morelli A, Vignozzi L, Maggi M, Adorini L. Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochim Biophys Acta 2011;1812:859–66
   Google Scholar
• Vignozzi L, Morelli A, Filippi S, et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011;8:57–77
   PubMed Web of Science ®Google Scholar
• Chen YH, Yang ZS, Wen CC, et al. Evaluation of the structure-activity relationship of flavonoids as antioxidants and toxicants of zebrafish larvae. Food Chem 2012;134:717–24
   PubMedGoogle Scholar
• Richter HG, Benson GM, Bleicher KH, et al. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorg Med Chem Lett 2011;21:1134–40
   PubMed Web of Science ®Google Scholar
• Richter HG, Benson GM, Blum D, et al. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorg Med Chem Lett 2011;21:191–4
   PubMed Web of Science ®Google Scholar
• Dixon SL, Smondyrev AM, Knoll EH, et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 2006;20:647–71
   PubMed Web of Science ®Google Scholar
• Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177–96
   PubMed Web of Science ®Google Scholar
• Berendsen HJC, Spoel VD, Drunen RV. GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun 1995;95:43–56
   Web of Science ®Google Scholar
• van Gunsteren WF, Billeter SR, Eising AA, et al. Biomolecular simulation: GROMOS96 manual and user guide. Zurich, Groningen: BIOMOS; 1996
   Google Scholar
• Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. LINCS: a linear constraint solver for molecular simulations. J Comp Chem 1996;18:1463–72
   Web of Science ®Google Scholar
• Miyamoto S, Kollman PA. SETTLE: an analytical version of the SHAKE and RATTLE algorithms for rigid water models. J Comput Chem 1992;13:952–62
   Web of Science ®Google Scholar
• Suryanarayanan V, Sudha A, Rajamanikandan S, et al. Atom-based 3D-QSAR studies on novel N-β-D-xylosylindole derivatives as SGLT2 inhibitors. Med Chem Res 2013;22:615–24
   Web of Science ®Google Scholar
• Choudhari PB, Bhatia MS. 3D QSAR, docking studies, and pharmacophore modeling of selected factor Xa inhibitors. Med Chem Res 2012;21:1427–32
   Google Scholar
• Guasch L, Sala E, Valls C, et al. Development of docking-based 3D-QSAR models for PPAR gamma full agonists. J Mol Graph Model 2012;36:1–9
   PubMed Web of Science ®Google Scholar
• Faraldo-Gomez JD, Smith GR, Sansom MS. Molecular dynamics simulation of the bacterial outer membrane protein FhuA: a comparative study of the ferrichrome-free and bound states. Biophys J 2003;85:1406–20
   PubMed Web of Science ®Google Scholar